Biotron recently announced a Shareholder Purchase Plan (SPP), highlighting its tight financial situation and seeking support from shareholders again. If the fundraising fails to reach the minimum target of $500,000, the company will appoint a voluntary administrator and wind up while still solvent. Clearly, Biotron has reached a critical crossroads.While the company has made many mistakes in the past, but it is meaningless to criticize now. Biotron's statement this time is not unreasonable - it does take time to evaluate and negotiate. I still believe in Biotron’s science. Its viroporin antagonists, uniquely combining direct-acting antiviral and immunomodulatory activities , are at the forefront of the field. This makes them a rare asset in the market and should carry intrinsic value.Furthermore, I trust the expertise and reputation of C14 Consulting Group LLC, which has a history of successful cases. Biotron has also stated that progress has been made since engaging their services.Based on these two factors, I am willing to take the risk and participate in the SPP, provided my financial situation allows it. Do your best, if you are still a existing shareholder, otherwise the company will enter liquidation, and the shareholders will get nothing. Let's take it as the last time. It is also time for the board of directors to be reorganized when the company is revitalized
Expand
(20min delay)